MET inhibition enhances PARP inhibitor efficacy in castration‐resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways

Up to 30% of patients with metastatic castration‐resistant prostate cancer (CRPC) patients carry altered DNA damage response genes, enabling the use of poly adenosine diphosphate–ribose polymerase (PARP) inhibitors in advanced CRPC. The proto‐oncogene mesenchymal–epithelial transition (MET) is cruci...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Sihai, Dai, Zhihong, Wang, Liang, Gao, Xiang, Yang, Liqin, Wang, Zhenwei, Wang, Qi, Liu, Zhiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650038/
https://www.ncbi.nlm.nih.gov/pubmed/34761497
http://dx.doi.org/10.1111/jcmm.17037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650038/
https://www.ncbi.nlm.nih.gov/pubmed/34761497
http://dx.doi.org/10.1111/jcmm.17037

Ejemplares similares